Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...
Gilead Sciences Inc. stock rises Wednesday, still underperforms market
Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...
Christianity Today7d
The Balm of Gilead Grows Again, Maybe
And other news from Christians around the world.
BioSpace2d
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
'Double moonshot' launch highlights global race to the moon
Two moon landers, one from Japan's ispace and another from U.S. space firm Firefly, began their journeys into space on Wednesday (January 15) with SpaceX's unusual double moonshot launch, underscoring ...
FierceBiotech4d
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Business Wire4d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
bovnews14h
Why Did Morgan Stanley Raised Gilead Sciences Inc (GILD) Stock Rating?
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...
Gilead Sciences Inc. stock rises Monday, still underperforms market
Shares of Gilead Sciences Inc. GILD inched 0.07% higher to $89.94 Monday, on what proved to be an all-around positive trading ...